The global hemophilia treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market during the forecast period includes the rising burden of rare disorders among people globally. Hemophilia is a rare health condition in which an individual’s blood is not able to clot normally due to a lack of adequate blood-clotting factors. Manufacturers operating in the market are consistently focused on the development of novel and more efficient drugs. Hemophilia is caused by gene mutation, and around 70% of hemophilia cases are inherited. Moreover, the increasing awareness of such rare diseases among the population and government participation in the prevention and control of these life-threatening diseases are further driving the market growth.

In order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in July 2021, BioMarin Pharmaceutical Inc. announced the European Medicines Agency (EMA) approval for marketing authorisation of its investigational gene therapy valoctocogene roxaparvovec, for adults who are dealing with severe Hemophilia A. In May 2021, CSL Behring announced the completion of commercialisation and licensing agreement with uniQure for etranacogene dezaparvovec (AMT-061) for the treatment of Hemophilia B. The drug candidate is developed by uniQure and is currently in the Phase III clinical study.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Pfizer Inc., Novo Nordisk A/S, and Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hemophilia Treatment Drugs Market Report by Segment

By Drug Class

• Desmopressin

• Antifibrinolytic Agents

• Recombinant Coagulation Factor Concentrates

• Plasma Derived Coagulation Factor Concentrates

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Global Hemophilia Treatment Drugs Market by Region